Karnofsky Performance Status Scale (KPS Scale)



Similar documents
Alcohol Use Disorder Identification Test Self-Report Version (AUDIT-SR)

PharmaSUG Paper DS15

SDTM AND ADaM: HANDS-ON SOLUTIONS

PhUSE Paper CD13

The CDISC Study Data Tabulation Model (SDTM): History, Perspective, and Basics Fred Wood Principal Consultant, Octagon Research Solutions

CDISC Journal. Regulatory Submissions for Medical Devices and Diagnostics: The Basics

SDTM Validation: Methodologies and Tools

SDTM-ETL TM. The user-friendly ODM SDTM Mapping software package. Transforming operational clinical data into SDTM datasets is not an easy process.

Challenges of Processing Questionnaire Data from Collection to SDTM to ADaM and Solutions using SAS

CDISC standards and data management The essential elements for Advanced Review with Electronic Data

New features in SDTM-ETL v SDTM-ETL TM. New Features in version 1.2

Vasanth Kumar Kunitala et al, SPJTS.1.(2), ISSN

CDISC Asthma Therapeutic Area Data Standards User Guide Yes, it is interesting! Paul Terrill

Metadata Submission Guidelines Appendix to the Study Data Tabulation Model Implementation Guide

Note: See 7.7 Representations and Warranties, Limitations of Liability, and Disclaimer.

Analysis Data Model (ADaM)

ABSTRACT On October 1st, 2008, CDASH released the first 16 common CRF streams (or domains) for use by the Pharmaceutical Industry.

USE CDISC SDTM AS A DATA MIDDLE-TIER TO STREAMLINE YOUR SAS INFRASTRUCTURE

PharmaSUG2010 HW06. Insights into ADaM. Matthew Becker, PharmaNet, Cary, NC, United States

Therapeutic Area Data Standards User Guide for Multiple Sclerosis Version 1.0

Einführung in die CDISC Standards CDISC Standards around the World. Bron Kisler (CDISC) & Andrea Rauch DVMD Tagung

Business & Decision Life Sciences CDISC Workshop: From SDTM to ADaM: Mapping Methodologies

Client Summary Palliative Care

ADaM Implications from the CDER Data Standards Common Issues and SDTM Amendment 1 Documents Sandra Minjoe, Octagon Research Solutions, Wayne, PA

Data Conversion to SDTM: What Sponsors Can Do to Facilitate the Process

Implementing CDASH Standards Into Data Collection and Database Design. Robert Stemplinger ICON Clinical Research

Trials and Tribulations of SDTM Trial Design

Strategies and Practical Considerations for Creating CDISC SDTM Domain Data Sets from Existing CDM Data Sets

Overview of CDISC Implementation at PMDA. Yuki Ando Senior Scientist for Biostatistics Pharmaceuticals and Medical Devices Agency (PMDA)

The ADaM Solutions to Non-endpoints Analyses

PharmaSUG Paper DS02

Business & Decision Life Sciences What s new in ADaM

A Brief Introduc/on to CDISC SDTM and Data Mapping

Introduction to the CDISC Standards

Lessons on the Metadata Approach. Dave Iberson- Hurst 9 th April 2014 CDISC Euro Interchange 2014

STUDY DATA TECHNICAL CONFORMANCE GUIDE

Implementation of SDTM in a pharma company with complete outsourcing strategy. Annamaria Muraro Helsinn Healthcare Lugano, Switzerland

PharmaSUG 2016 Paper IB10

Data Standards and the National Cardiovascular Research Infrastructure (NCRI)

Guideline for Estimating Length of Survival in Palliative Patients

STUDY DATA TECHNICAL CONFORMANCE GUIDE

STUDY DATA TECHNICAL CONFORMANCE GUIDE

Copyright 2012, SAS Institute Inc. All rights reserved. VISUALIZATION OF STANDARD TLFS FOR CLINICAL TRIAL DATA ANALYSIS

Using the SAS XML Mapper and ODS PDF to create a PDF representation of the define.xml (that can be printed)

Implementing the CDISC standards into an existing CDMS

Karnofsky/Lansky Performance Status

Therapeutic Area Standards (TAS) Initiative Project Plan

Common Misunderstandings about ADaM Implementation

Use of standards: can we really be analysis ready?

CDISC Roadmap Outline: Further development and convergence of SDTM, ODM & Co

Analysis Data Model: Version 2.0

BRIDGing CDASH to SAS: How Harmonizing Clinical Trial and Healthcare Standards May Impact SAS Users Clinton W. Brownley, Cupertino, CA

CDER/CBER s Top 7 CDISC Standards Issues

Optimizing Safety Surveillance During Clinical Trials Using Data Visualization Tools

Extracting the value of Standards: The Role of CDISC in a Pharmaceutical Research Strategy. Frank W. Rockhold, PhD* and Simon Bishop**

Practical application of SAS Clinical Data Integration Server for conversion to SDTM data

Programme Guide PGDCDM

Electronic Submission of Regulatory Information, and Creating an Electronic Platform for Enhanced Information Management

PK IN DRUG DEVELOPMENT. CDISC management of PK data. Matteo Rossini Milan, 9 February 2010

ADaM Supplement to the TAUG-Diabetes Version 1.0 (Draft)

Analysis Data Model (ADaM) Implementation Guide

Robust tools to Create Define.xml v2.0 based submission components for SDTM, ADAM & SEND Vineet Jain, Independent Consultant

PharmaSUG Paper HS01. CDASH Standards for Medical Device Trials: CRF Analysis. Parag Shiralkar eclinical Solutions, a Division of Eliassen Group

Development of an open metadata schema for Prospective Clinical Research (openpcr)

Bridging Statistical Analysis Plan and ADaM Datasets and Metadata for Submission

Clinical Trial Data Integration: The Strategy, Benefits, and Logistics of Integrating Across a Compound

Metadata and ADaM.

SAS CLINICAL TRAINING

Using SAS Data Integration Studio to Convert Clinical Trials Data to the CDISC SDTM Standard Barry R. Cohen, Octagon Research Solutions, Wayne, PA

Training/Internship Brochure Advanced Clinical SAS Programming Full Time 6 months Program

A white paper presented by: Barry Cohen Director, Clinical Data Strategies Octagon Research Solutions, Inc. Wayne, PA

Did you know? Accenture can deliver business outcome-focused results for your life sciences research & development organization like these:

CDISC Data Standards Can Facilitate Composition of Adverse Event Narratives

CDISC SDTM/ADaM Pilot Project 1 Project Report

How to build ADaM from SDTM: A real case study

Clinical Data Acquisition Standards Harmonization: Basic Data Collection Fields for Case Report Forms

Understanding CDISC Basics

Current Status and Future Perspectives for Systemization of Clinical Study related the issues of CDISC in USA and other

ADaM or SDTM? A Comparison of Pooling Strategies for Integrated Analyses in the Age of CDISC

Rationale and vision for E2E data standards: the need for a MDR

Streamlining the Flow of Clinical Trial Data: EHR to EDC to Sponsor

CREATING SV AND SE FIRST Henry B. Winsor, WinsorWorks, Limited, San Mateo, CA Mario Widel, Genentech, Inc., South San Francisco, CA

Development of CDISC Tuberculosis Data Standards

End-to-End E-Clinical Coverage with Oracle Health Sciences InForm GTM

Accenture Accelerated R&D Services: CDISC Conversion Service Overview

Meta-programming in SAS Clinical Data Integration

Medicare Part D Hospice Care Hospice Information for Medicare Part D Plans

Business & Decision Life Sciences

Managing and Integrating Clinical Trial Data: A Challenge for Pharma and their CRO Partners

UTILIZING CDISC STANDARDS TO DRIVE EFFICIENCIES WITH OPENCLINICA Mark Wheeldon CEO, Formedix Boston June 21, 2013

Pharmaceutical Applications

WHITE PAPER. CONVERTING SDTM DATA TO ADaM DATA AND CREATING SUBMISSION READY SAFETY TABLES AND LISTINGS. SUCCESSFUL TRIALS THROUGH PROVEN SOLUTIONS

A Macro to Create Data Definition Documents

Expert Witness Services for Personal Injury Lawyers

Guidance for Industry

Considering De-Identification? Legacy Data. Kymberly Lee 16-Jul-2015

Transcription:

Karnofsky Performance Status Scale (KPS Scale) Questionnaire Supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials Prepared by CDISC and Analgesic Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) Notes to Readers This implementation guide is intended to be used with other CDISC User Guides for specific Therapeutic/Disease Areas and follows the CDISC Study Data Tabulation Model Implementation Guide for Human Clinical trials. Revision History Date Version Summary of Changes 2012-03-03 0.1 Karnofsky performance status scale (KPSS) Draft 2012-08-07 1.0 Karnofsky performance status scale (KPSS)

1 Introduction This document describes the CDISC implementation of the Karnofsky Performance Status Scale (KPS Scale) questionnaire, a standard questionnaire administered on a CRF that is typically used in clinical trials to measure pain response. The KPS Scale CRF preceded the CDISC CDASH CRF standards and based on its copyright status, cannot be modified to CDASH standards. The representation of data collected for this questionnaire is based on the Study Data Tabulation Model Implementation Guide (SDTMIG) QS domain table, which can be found at the CDISC website at: (http://www.cdisc.org/sdtm) These specific implementation details for this specific questionnaire are meant to be used in conjunction with the SDTMIG, but are recorded separately since this questionnaire may be used in many different therapeutic area implementations. All questionnaire documentation can be found on the CDISC web site at: (http://www.cdisc.org/content2909) The CDISC Intellectual Property Policy can be found on the CDISC web site at: (http://www.cdisc.org/sdtm) 1.1 Representations and Warranties, Limitations of Liability, and Disclaimers This document is a supplement to the Study Data Tabulation Model Implementation Guide for Human Clinical Trials and is covered under Appendix F of that document, which describes representations, warranties, limitations of liability, and disclaimers. Please see Appendix F of the SDTMIG for a complete version of this material. 2 Copyright Status This instrument is in the public domain. CDISC has included the Karnofsky Performance Status Scale (KPS Scale) as part of CDISC Data Standards. This means that CDISC developed QSTESTCD and QSTEST for each question based on the actual question text on the questionnaire. There may be many versions of this questionnaire in the public domain. CDISC has chosen to use this version as the data standard. The CDISC documentation of this instrument consists of: (1) controlled terminology, (2) standard database structure with examples and (3) case report forms annotated with the CDISC SDTMIG submission values. CDISC has developed this documentation at no cost to users of the instrument. 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 2

3 The QS Domain Model 3.1 Assumptions for Questionnaire Domain Model All assumptions for the QS domain from the SDTMIG apply for this supplemental implementation guide including those referenced in the CDISC notes. Additionally, the following assumption applies to the KARNOFSKY PERFORMANCE STATUS SCALE: 1. Karnofsky Performance Status Scale (KPSS): KPSS allows patients to be classified as to their functional impairment. This can be used to compare effectiveness of different therapies and to assess the prognosis in individual patients. The lower the Karnofsky score, the worse the survival for most serious illnesses. 2. Visual analog or numeric rating scales used within a questionnaire with a range of text and numeric values are indicated in the SUPPQS domain with: QNAM=RNGTXTLO QNAM=RNGTXTHI QNAM=RNGVALLO QNAM=RNGVALHI By storing this information in SUPPQS, it is available for interpretation purposes. The SDS QS Team is researching alternative methods to handle this data, but until a new method is identified, this will be the agreed approach. 3. The evaluator of the questionnaire is stored in QSEVAL and for the KPSS form the INVESTIGATOR provides the evaluation. 4. Terminology: a. QSCAT, QSTESTCD and QSTEST are approved CDISC controlled terminology. b. Additional standardization of the QSORRES, QSSTRESC and QSSTRESN fields can be found in Section 4: Mapping Strategy. 3.2 Example for Karnofsky Performance Status Scale Domain Model The KPSS example below shows the terminology for QSCAT, QSTEST, QSTESTCD and QSORRES that should be utilized for this scale. Values for QSORRES are for prospective data collection. Sponsors mapping legacy data should retain legacy values for QSORRES. A full list of value sets for QSORRES, QSSTRESC and QSSTRESN fields is provided in Section 4: Mapping Strategy. 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 3

Example 1: KARNOFSKY PERFORMANCE STATUS SCALE (KPSS) This example shows data from one subject collected at three visits for a KPSS questionnaire. The example uses standard controlled terminology for QSTESTCD, QSTEST, QSCAT and QSORRES for the KPSS measure. Rows 1-3: Represent the question from the KPSS Form for three visits for SUBJID= 2324-P0001. All original results are represented with the standard terminology in QSORRES. This result is then transformed into a Standard Numeric score in QSSTRESN. QS.XPT Row STUDYID DOMAIN USUBJID QSSEQ QSTESTCD QSTEST QSCAT QSORRES QSSTRESC QSSTRESN QSSTRESU 2324- KPSS-Karnofsky KPS 1 STUDYX QS 1 KPSS01 P0001 Performance Status Scale Disabled; requires special care and assistance. 40 40 % 2324- KPSS-Karnofsky KPS Requires considerable assistance and frequent 2 STUDYX QS 2 KPSS01 P0001 Performance Status Scale medical care. 50 50 % 2324- KPSS-Karnofsky KPS Requires occasional assistance, but is able to care 3 STUDYX QS 3 KPSS01 P0001 Performance Status Scale for most of his personal needs. 60 60 % Row QSEVAL VISITNUM QSDTC 1 (cont) INVESTIGATOR 1 2011-06-11 2 (cont) INVESTIGATOR 2 2011-09-13 3 (cont) INVESTIGATOR 3 2011-12-21 The data range text and numeric values for data collection needs to be populated in SUPPQS as follows. The standard terminology for QNAM and QLABEL are listed below. SUPPQS.XPT STUDYID RDOMAIN USUBJID IDVAR IDVARVAL QNAM QLABEL QVAL QORIG QEVAL STUDY01 QS 2324-P0001 QSSEQ 1 RNGTXTLO Range Text Lo Dead CRF STUDY01 QS 2324-P0001 QSSEQ 1 RNGTXTHI Range Text Hi Normal no complaints; no evidence of disease. CRF STUDY01 QS 2324-P0001 QSSEQ 1 RNGVALLO Range Value Lo 0 CRF STUDY01 QS 2324-P0001 QSSEQ 1 RNGVALHI Range Value HI 100 CRF STUDY01 QS 2324-P0001 QSSEQ 2 RNGTXTLO Range Text Lo Dead CRF STUDY01 QS 2324-P0001 QSSEQ 2 RNGTXTHI Range Text Hi Normal no complaints; no evidence of disease. CRF STUDY01 QS 2324-P0001 QSSEQ 2 RNGVALLO Range Value Lo 0 CRF STUDY01 QS 2324-P0001 QSSEQ 2 RNGVALHI Range Value HI 100 CRF STUDY01 QS 2324-P0001 QSSEQ 3 RNGTXTLO Range Text Lo Dead CRF STUDY01 QS 2324-P0001 QSSEQ 3 RNGTXTHI Range Text Hi Normal no complaints; no evidence of disease. CRF STUDY01 QS 2324-P0001 QSSEQ 3 RNGVALLO Range Value Lo 0 CRF STUDY01 QS 2324-P0001 QSSEQ 3 RNGVALHI Range Value HI 100 CRF 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 4

4 SDTM Mapping Strategy KPSS specific mapping strategy: This section is used for reference with the annotated CRF for further details on the CRF data capture and to understand the alignment of the questionnaire to the SDTM QS domain. It also provides guidance on how the result variables (QSORRES, QSORRESU, QSSTRESC, QSSTRESN, and QSSTRESU) should be populated for each questionnaire. If a result variable is not included in the table for a questionnaire, it should not be populated. QSTESTCD= KPSS01 QSTEST= KPSS-Karnofsky Performance Status QSORRES QSSTRESC QSSTRESN QSSTRESU Normal no complaints; no evidence of disease. 100 100 % Able to carry on normal activity; minor signs or symptoms of disease. 90 90 % Normal activity with effort; some signs or symptoms of disease. 80 80 % Cares for self; unable to carry on normal activity or to do active work. 70 70 % Requires occasional assistance, but is able to care for most of his personal needs. 60 60 % Requires considerable assistance and frequent medical care. 50 50 % Disabled; requires special care and assistance. 40 40 % Severely disabled; hospital admission is indicated although death not imminent. 30 30 % Very sick; hospital admission necessary; active supportive treatment necessary. 20 20 % Moribund; fatal processes progressing rapidly. 10 10 % Dead 0 0 % 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 5

SUPPLEMENTAL QUALIFIERS NAME CODES The following table contains an additional standard name codes for use in the Supplemental Qualifiers for Questionnaires (SUPPQS) special-purpose datasets. QNAM QLABEL Applicable Domains RNGTXTLO Range Text Lo QS RNGTXTHI Range Text Hi QS RNGVALLO Range Value Lo QS RNGVALHI Range Value HI QS End of Document 2012 Clinical Data Interchange Standards Consortium, Inc. All rights reserved Page 6